THERALASE TECHNOLOGIES INC (TLT.CA) Stock Fundamental Analysis
Canada - TSX Venture Exchange - TSX-V:TLT - CA88337V1004 - Common Stock
0.185 CAD
-0.01 (-5.13%)
TLT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 18 industry peers in the Health Care Equipment & Supplies industry. TLT has a bad profitability rating. Also its financial health evaluation is rather negative. TLT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLT has reported negative net income.
TLT had a negative operating cash flow in the past year.
In the past 5 years TLT always reported negative net income.
TLT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TLT has a Return On Assets (-141.86%) which is comparable to the rest of the industry.
The Return On Equity of TLT (-335.23%) is better than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.86% | ||
| ROE | -335.23% | ||
| ROIC | N/A |
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TLT has a Gross Margin (55.81%) which is in line with its industry peers.
In the last couple of years the Gross Margin of TLT has grown nicely.
The Profit Margin and Operating Margin are not available for TLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
2. Health
2.1 Basic Checks
TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLT has more shares outstanding
Compared to 1 year ago, TLT has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -19.41, we must say that TLT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TLT (-19.41) is better than 61.11% of its industry peers.
A Debt/Equity ratio of 0.13 indicates that TLT is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.13, TLT is doing good in the industry, outperforming 77.78% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -19.41 |
ROIC/WACCN/A
WACC7.74%
2.3 Liquidity
TLT has a Current Ratio of 0.96. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of TLT (0.96) is better than 72.22% of its industry peers.
TLT has a Quick Ratio of 0.96. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.62, TLT is doing good in the industry, outperforming 72.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
TLT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.81%, which is quite impressive.
TLT shows a decrease in Revenue. In the last year, the revenue decreased by -3.45%.
The Revenue has been growing slightly by 1.40% on average over the past years.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-3.45%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-19.6%
3.2 Future
Based on estimates for the next years, TLT will show a very strong growth in Earnings Per Share. The EPS will grow by 37.61% on average per year.
The Revenue is expected to grow by 256.32% on average over the next years. This is a very strong growth
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
TLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLT's earnings are expected to grow with 37.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
5. Dividend
5.1 Amount
No dividends for TLT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:TLT (11/21/2025, 7:00:00 PM)
0.185
-0.01 (-5.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.83%
Ins Owner ChangeN/A
Market Cap45.84M
Revenue(TTM)1.03M
Net Income(TTM)-4.28M
Analysts84.44
Price Target0.71 (283.78%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.63%
Min EPS beat(2)-94.17%
Max EPS beat(2)2.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-24.53%
Min Revenue beat(2)-55.73%
Max Revenue beat(2)6.67%
Revenue beat(4)3
Avg Revenue beat(4)88.3%
Min Revenue beat(4)-55.73%
Max Revenue beat(4)236.89%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)40%
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 42.92 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 35.91 | ||
| P/tB | 35.91 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -141.86% | ||
| ROE | -335.23% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.81% | ||
| FCFM | N/A |
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
F-Score4
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.13 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 34.64% | ||
| Cap/Sales | 8.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | -19.41 |
F-Score4
WACC7.74%
ROIC/WACCN/A
Cap/Depr(3y)14.29%
Cap/Depr(5y)27.96%
Cap/Sales(3y)3.87%
Cap/Sales(5y)8.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y39.41%
EPS Next 2Y-34.82%
EPS Next 3Y37.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.45%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-19.6%
Revenue Next Year17.72%
Revenue Next 2Y93.98%
Revenue Next 3Y256.32%
Revenue Next 5YN/A
EBIT growth 1Y2.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.52%
OCF growth 3YN/A
OCF growth 5YN/A
THERALASE TECHNOLOGIES INC / TLT.CA FAQ
What is the ChartMill fundamental rating of THERALASE TECHNOLOGIES INC (TLT.CA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to TLT.CA.
What is the valuation status of THERALASE TECHNOLOGIES INC (TLT.CA) stock?
ChartMill assigns a valuation rating of 1 / 10 to THERALASE TECHNOLOGIES INC (TLT.CA). This can be considered as Overvalued.
How profitable is THERALASE TECHNOLOGIES INC (TLT.CA) stock?
THERALASE TECHNOLOGIES INC (TLT.CA) has a profitability rating of 1 / 10.
What is the earnings growth outlook for THERALASE TECHNOLOGIES INC?
The Earnings per Share (EPS) of THERALASE TECHNOLOGIES INC (TLT.CA) is expected to grow by 39.41% in the next year.